{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T01:34:35Z","timestamp":1768440875964,"version":"3.49.0"},"reference-count":83,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2018,7,1]],"date-time":"2018-07-01T00:00:00Z","timestamp":1530403200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100006436","name":"Celgene","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100006436","id-type":"DOI","asserted-by":"crossref"}]},{"name":"LEO Pharma"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","theclinics.com","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Dermatologic Clinics"],"published-print":{"date-parts":[[2018,7]]},"DOI":"10.1016\/j.det.2018.02.014","type":"journal-article","created":{"date-parts":[[2018,4,16]],"date-time":"2018-04-16T23:14:38Z","timestamp":1523920478000},"page":"325-334","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"title":["Immunomodulating Agents as Antipruritics"],"prefix":"10.1016","volume":"36","author":[{"given":"Stephen","family":"Erickson","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zachary","family":"Nahmias","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ilana S.","family":"Rosman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brian S.","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.det.2018.02.014_bib1","doi-asserted-by":"crossref","first-page":"291","DOI":"10.2340\/00015555-0305","article-title":"Clinical classification of itch: a position paper of the international forum for the study of itch","volume":"87","author":"Stander","year":"2007","journal-title":"Acta Derm Venereol"},{"issue":"10","key":"10.1016\/j.det.2018.02.014_bib2","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1001\/archdermatol.2011.178","article-title":"The impact of pruritus on quality of life: the skin equivalent of pain","volume":"147","author":"Kini","year":"2011","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.det.2018.02.014_bib3","doi-asserted-by":"crossref","first-page":"e239","DOI":"10.1111\/j.1468-3083.2012.04578.x","article-title":"Relationship between itch and psychological status of patients with atopic dermatitis","volume":"27","author":"Chrostowska-Plak","year":"2013","journal-title":"J\u00a0Eur Acad Dermatol Venereol"},{"issue":"3","key":"10.1016\/j.det.2018.02.014_bib4","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1159\/000319862","article-title":"Prevalence of chronic pruritus in Germany: results of a cross-sectional study in a sample working population of 11,730","volume":"221","author":"Stander","year":"2010","journal-title":"Dermatology"},{"issue":"6","key":"10.1016\/j.det.2018.02.014_bib5","doi-asserted-by":"crossref","first-page":"674","DOI":"10.2340\/00015555-1159","article-title":"Prevalence, correlates and characteristics of chronic pruritus: a population-based cross-sectional study","volume":"91","author":"Matterne","year":"2011","journal-title":"Acta Derm Venereol"},{"issue":"4","key":"10.1016\/j.det.2018.02.014_bib6","doi-asserted-by":"crossref","first-page":"417","DOI":"10.2340\/00015555-1968","article-title":"Itch prevalence and characteristics in a Hispanic geriatric population: a comprehensive study using a standardized itch questionnaire","volume":"95","author":"Valdes-Rodriguez","year":"2015","journal-title":"Acta Derm Venereol"},{"issue":"7154","key":"10.1016\/j.det.2018.02.014_bib7","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1038\/nature06029","article-title":"A\u00a0gastrin-releasing peptide receptor mediates the itch sensation in the spinal cord","volume":"448","author":"Sun","year":"2007","journal-title":"Nature"},{"issue":"7","key":"10.1016\/j.det.2018.02.014_bib8","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1016\/j.cell.2009.11.034","article-title":"Sensory neuron-specific GPCR Mrgprs are itch receptors mediating chloroquine-induced pruritus","volume":"139","author":"Liu","year":"2009","journal-title":"Cell"},{"issue":"3","key":"10.1016\/j.det.2018.02.014_bib9","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1016\/j.jaci.2014.11.001","article-title":"The 3 major types of innate and adaptive cell-mediated effector immunity","volume":"135","author":"Annunziato","year":"2015","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"1","key":"10.1016\/j.det.2018.02.014_bib10","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1038\/nrd4624","article-title":"Targeting key proximal drivers of type 2 inflammation in disease","volume":"15","author":"Gandhi","year":"2015","journal-title":"Nat Rev Drug Discov"},{"issue":"1","key":"10.1016\/j.det.2018.02.014_bib11","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1056\/NEJM200101043440106","article-title":"Allergy and allergic diseases","volume":"344","author":"Mackay","year":"2001","journal-title":"N\u00a0Engl J Med"},{"issue":"6","key":"10.1016\/j.det.2018.02.014_bib12","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1007\/s40257-016-0213-5","article-title":"Current and emerging therapies for itch management in psoriasis","volume":"17","author":"Stull","year":"2016","journal-title":"Am J Clin Dermatol"},{"issue":"7","key":"10.1016\/j.det.2018.02.014_bib13","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1111\/all.12313","article-title":"The EAACI\/GA2LEN\/EDF\/WAO guideline for the definition, classification, diagnosis, and management of urticaria: the 2013 revision and update","volume":"69","author":"Zuberbier","year":"2014","journal-title":"Allergy"},{"issue":"1","key":"10.1016\/j.det.2018.02.014_bib14","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.iac.2013.07.009","article-title":"Pathology and classification of urticaria","volume":"34","author":"Greaves","year":"2014","journal-title":"Immunol Allergy Clin North Am"},{"issue":"1","key":"10.1016\/j.det.2018.02.014_bib15","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1007\/s12016-012-8326-y","article-title":"Pathogenic intracellular and autoimmune mechanisms in urticaria and angioedema","volume":"45","author":"Altman","year":"2013","journal-title":"Clin Rev Allergy Immunol"},{"issue":"3","key":"10.1016\/j.det.2018.02.014_bib16","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1007\/s12016-015-8488-5","article-title":"Mediators of chronic pruritus in atopic dermatitis: getting the itch out?","volume":"51","author":"Mollanazar","year":"2016","journal-title":"Clin Rev Allergy Immunol"},{"key":"10.1016\/j.det.2018.02.014_bib17","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1007\/978-3-662-44605-8_15","article-title":"Antihistamines and itch","volume":"226","author":"Thurmond","year":"2015","journal-title":"Handb Exp Pharmacol"},{"issue":"3","key":"10.1016\/j.det.2018.02.014_bib18","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1124\/jpet.105.087965","article-title":"Evaluation of histamine\u00a0H1-, H2-, and H3-receptor ligands at the human histamine H4 receptor: identification of 4-methylhistamine as the first potent and selective H4 receptor agonist","volume":"314","author":"Lim","year":"2005","journal-title":"J\u00a0Pharmacol Exp Ther"},{"key":"10.1016\/j.det.2018.02.014_bib19","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.neuropharm.2015.05.004","article-title":"The histamine H4-receptor and the central and peripheral nervous system: a critical analysis of the literature","volume":"106","author":"Schneider","year":"2016","journal-title":"Neuropharmacology"},{"issue":"1","key":"10.1016\/j.det.2018.02.014_bib20","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1124\/jpet.114.215749","article-title":"The histamine H4 receptor antagonist, JNJ 39758979, is effective in reducing histamine-induced pruritus in a randomized clinical study in healthy subjects","volume":"350","author":"Kollmeier","year":"2014","journal-title":"J\u00a0Pharmacol Exp Ther"},{"issue":"5","key":"10.1016\/j.det.2018.02.014_bib21","first-page":"386","article-title":"Usefulness of a short course of oral prednisone in antihistamine-resistant chronic urticaria: a retrospective analysis","volume":"20","author":"Asero","year":"2010","journal-title":"J\u00a0Investig Allergol Clin Immunol"},{"issue":"3","key":"10.1016\/j.det.2018.02.014_bib22","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/j.iac.2005.05.003","article-title":"Molecular mechanisms and cellular effects of glucocorticosteroids","volume":"25","author":"Barnes","year":"2005","journal-title":"Immunol Allergy Clin North Am"},{"issue":"2","key":"10.1016\/j.det.2018.02.014_bib23","doi-asserted-by":"crossref","first-page":"e31465","DOI":"10.1371\/journal.pone.0031465","article-title":"Calcineurin inhibitors suppress cytokine production from memory T cells and differentiation of naive T cells into cytokine-producing mature T cells","volume":"7","author":"Tsuda","year":"2012","journal-title":"PLoS One"},{"issue":"10","key":"10.1016\/j.det.2018.02.014_bib24","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1292\/jvms.70.1011","article-title":"Cyclosporine A inhibits transcription of cytokine genes and decreases the frequencies of IL-2 producing cells in feline mononuclear cells","volume":"70","author":"Kuga","year":"2008","journal-title":"J\u00a0Vet Med Sci"},{"issue":"4","key":"10.1016\/j.det.2018.02.014_bib25","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1038\/sj.bjp.0707002","article-title":"Role of calcineurin in the regulation of human lung mast cell and basophil function by cyclosporine and FK506","volume":"150","author":"Harrison","year":"2007","journal-title":"Br J Pharmacol"},{"issue":"4","key":"10.1016\/j.det.2018.02.014_bib26","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/j.jaad.2006.04.078","article-title":"Cyclosporine in chronic idiopathic urticaria: a double-blind, randomized, placebo-controlled trial","volume":"55","author":"Vena","year":"2006","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.det.2018.02.014_bib27","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/S0065-2776(06)93002-8","article-title":"Anti-IgE antibodies for the treatment of IgE-mediated allergic diseases","volume":"93","author":"Chang","year":"2007","journal-title":"Adv Immunol"},{"issue":"3","key":"10.1016\/j.det.2018.02.014_bib28","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/j.jaci.2004.06.032","article-title":"Omalizumab-induced reductions in mast cell Fc\u03b5RI expression and function","volume":"114","author":"Beck","year":"2004","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"10","key":"10.1016\/j.det.2018.02.014_bib29","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1056\/NEJMoa1215372","article-title":"Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria","volume":"368","author":"Maurer","year":"2013","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1016\/j.det.2018.02.014_bib30","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1038\/jid.2014.306","article-title":"Efficacy and safety of omalizumab in patients with chronic idiopathic\/spontaneous urticaria who remain symptomatic on H1 antihistamines: a randomized, placebo-controlled study","volume":"135","author":"Saini","year":"2015","journal-title":"J\u00a0Invest Dermatol"},{"issue":"5","key":"10.1016\/j.det.2018.02.014_bib31","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1111\/jdv.13599","article-title":"ETFAD\/EADV Eczema task force 2015 position paper on diagnosis and treatment of atopic dermatitis in adult and paediatric patients","volume":"30","author":"Wollenberg","year":"2016","journal-title":"J\u00a0Eur Acad Dermatol Venereol"},{"issue":"8","key":"10.1016\/j.det.2018.02.014_bib32","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1038\/nri.2017.39","article-title":"Early life factors that affect allergy development","volume":"17","author":"Reynolds","year":"2017","journal-title":"Nat Rev Immunol"},{"issue":"7545","key":"10.1016\/j.det.2018.02.014_bib33","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1038\/nature14052","article-title":"Commensal\u2013dendritic-cell interaction specifies a unique protective skin immune signature","volume":"520","author":"Naik","year":"2015","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.det.2018.02.014_bib34","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.jaci.2016.07.029","article-title":"Skin microbiome before development of atopic dermatitis: early colonization with commensal staphylococci at 2 months is associated with a lower risk of atopic dermatitis at 1 year","volume":"139","author":"Kennedy","year":"2017","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"3","key":"10.1016\/j.det.2018.02.014_bib35","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1038\/jid.2014.401","article-title":"Innate lymphoid cells in the skin","volume":"135","author":"Kim","year":"2015","journal-title":"J\u00a0Invest Dermatol"},{"issue":"2","key":"10.1016\/j.det.2018.02.014_bib36","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1016\/j.jaci.2013.10.048","article-title":"A\u00a0sensory neuron-expressed IL-31 receptor mediates T helper cell-dependent itch: involvement of TRPV1 and TRPA1","volume":"133","author":"Cevikbas","year":"2014","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"47","key":"10.1016\/j.det.2018.02.014_bib37","doi-asserted-by":"crossref","first-page":"E7572","DOI":"10.1073\/pnas.1606608113","article-title":"IL-33\/ST2 signaling excites sensory neurons and mediates itch response in a mouse model of poison ivy contact allergy","volume":"113","author":"Liu","year":"2016","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"2","key":"10.1016\/j.det.2018.02.014_bib38","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.cell.2013.08.057","article-title":"The epithelial cell-derived atopic dermatitis cytokine TSLP activates neurons to induce itch","volume":"155","author":"Wilson","year":"2013","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.det.2018.02.014_bib39","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.cell.2017.08.006","article-title":"Sensory neurons co-opt classical immune signaling pathways to mediate chronic itch","volume":"171","author":"Oetjen","year":"2017","journal-title":"Cell"},{"issue":"3","key":"10.1016\/j.det.2018.02.014_bib40","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1111\/j.1398-9995.2005.00977.x","article-title":"Onset of pruritus relief with pimecrolimus cream 1% in adult patients with atopic dermatitis: a randomized trial","volume":"61","author":"Kaufmann","year":"2006","journal-title":"Allergy"},{"issue":"1","key":"10.1016\/j.det.2018.02.014_bib41","doi-asserted-by":"crossref","first-page":"17","DOI":"10.2174\/187152807780077318","article-title":"Highly selective phosphodiesterase 4 inhibitors for the treatment of allergic skin diseases and psoriasis","volume":"6","author":"B\u00e4umer","year":"2007","journal-title":"Inflamm Allergy Drug Targets"},{"issue":"5","key":"10.1016\/j.det.2018.02.014_bib42","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1111\/exd.12377","article-title":"Topical E6005, a novel phosphodiesterase 4 inhibitor, attenuates spontaneous itch-related responses in mice with chronic atopy-like dermatitis","volume":"23","author":"Andoh","year":"2014","journal-title":"Exp Dermatol"},{"issue":"3","key":"10.1016\/j.det.2018.02.014_bib43","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/j.jaad.2016.05.046","article-title":"Efficacy and safety of crisaborole ointment, a novel, nonsteroidal phosphodiesterase 4 (PDE4) inhibitor for the topical treatment of atopic dermatitis (AD) in children and adults","volume":"75","author":"Paller","year":"2016","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"3","key":"10.1016\/j.det.2018.02.014_bib44","first-page":"110","article-title":"Th2 cytokines and atopic dermatitis","volume":"2","author":"Brandt","year":"2011","journal-title":"J\u00a0Clin Cell Immunol"},{"issue":"2","key":"10.1016\/j.det.2018.02.014_bib45","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1056\/NEJMoa1314768","article-title":"Dupilumab treatment in adults with moderate-to-severe atopic dermatitis","volume":"371","author":"Beck","year":"2014","journal-title":"N\u00a0Engl J Med"},{"issue":"24","key":"10.1016\/j.det.2018.02.014_bib46","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1056\/NEJMoa1610020","article-title":"Two phase 3 trials of dupilumab versus placebo in atopic dermatitis","volume":"375","author":"Simpson","year":"2016","journal-title":"N\u00a0Engl J Med"},{"issue":"10013","key":"10.1016\/j.det.2018.02.014_bib47","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/S0140-6736(15)00388-8","article-title":"Efficacy and safety of dupilumab in adults with moderate-to-severe atopic dermatitis inadequately controlled by\u00a0topical treatments: a randomised, placebo-controlled, dose-ranging phase 2b trial","volume":"387","author":"Tha\u00e7i","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.det.2018.02.014_bib48","doi-asserted-by":"crossref","unstructured":"Wollenberg A, Birrell C, Dawson MA, et\u00a0al. A phase 2b dose-ranging efficacy and safety study of tralokinumab in adult patients with moderate to severe atopic dermatitis. Presented at: 75th Annual AAD Meeting. Orlando (FL), March 3\u20137, 2017. [abstract: 4496].","DOI":"10.25251\/skin.2.supp.28"},{"issue":"5","key":"10.1016\/j.det.2018.02.014_bib49","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1080\/1744666X.2017.1298443","article-title":"Commonality of the IL-4\/IL-13 pathway in atopic diseases","volume":"13","author":"Gandhi","year":"2017","journal-title":"Expert Rev Clin Immunol"},{"key":"10.1016\/j.det.2018.02.014_bib50","unstructured":"Simpson E, Flohr C, Eichenfield L, et\u00a0al. Efficacy and\u00a0safety of lebrikizumab in patients with atopic dermatitis: a phase II randomized, controlled trial (TREBLE). Presented at: 25th EADV Congress. Vienna (Austria), September 28\u2013October 2, 2016."},{"issue":"1","key":"10.1016\/j.det.2018.02.014_bib51","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1146\/annurev-biophys-051013-022826","article-title":"Itch mechanisms and circuits","volume":"43","author":"Han","year":"2014","journal-title":"Annu Rev Biophys"},{"issue":"7","key":"10.1016\/j.det.2018.02.014_bib52","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1038\/ni1084","article-title":"Interleukin 31, a cytokine produced by activated T cells, induces dermatitis in mice","volume":"5","author":"Dillon","year":"2004","journal-title":"Nat Immunol"},{"issue":"2","key":"10.1016\/j.det.2018.02.014_bib53","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/j.jaci.2005.10.033","article-title":"IL-31: a new link between T cells and pruritus in atopic skin inflammation","volume":"117","author":"Sonkoly","year":"2006","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"1","key":"10.1016\/j.det.2018.02.014_bib54","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1111\/j.1600-0625.2008.00766.x","article-title":"Anti-interleukin-31-antibodies ameliorate scratching behaviour in NC\/Nga mice: a model of atopic dermatitis","volume":"18","author":"Grimstad","year":"2009","journal-title":"Exp Dermatol"},{"issue":"2","key":"10.1016\/j.det.2018.02.014_bib55","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/j.jaci.2008.05.047","article-title":"Correlation of IL-31 serum levels with severity of atopic dermatitis","volume":"122","author":"Raap","year":"2017","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"6","key":"10.1016\/j.det.2018.02.014_bib56","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1111\/j.1600-0625.2012.01487.x","article-title":"Increased frequencies of IL-31-producing T cells are found in chronic atopic dermatitis skin","volume":"21","author":"Szegedi","year":"2012","journal-title":"Exp Dermatol"},{"issue":"9","key":"10.1016\/j.det.2018.02.014_bib57","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1056\/NEJMoa1606490","article-title":"Anti\u2013interleukin-31 receptor A antibody for atopic dermatitis","volume":"376","author":"Ruzicka","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.det.2018.02.014_bib58","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1111\/j.1600-065X.2011.01027.x","article-title":"Atopic dermatitis: a disease of altered skin barrier and immune dysregulation","volume":"242","author":"Boguniewicz","year":"2011","journal-title":"Immunol Rev"},{"issue":"170","key":"10.1016\/j.det.2018.02.014_bib59","doi-asserted-by":"crossref","first-page":"170ra16","DOI":"10.1126\/scitranslmed.3005374","article-title":"TSLP elicits IL-33-independent innate lymphoid cell responses to promote skin inflammation","volume":"5","author":"Kim","year":"2013","journal-title":"Sci Transl Med"},{"issue":"7","key":"10.1016\/j.det.2018.02.014_bib60","doi-asserted-by":"crossref","first-page":"3717","DOI":"10.4049\/jimmunol.1401307","article-title":"Basophils promote innate lymphoid cell responses in inflamed skin","volume":"193","author":"Kim","year":"2014","journal-title":"J\u00a0Immunol"},{"issue":"2","key":"10.1016\/j.det.2018.02.014_bib61","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.jdermsci.2017.07.003","article-title":"Increased frequencies of basophils, type 2 innate lymphoid cells and Th2 cells in skin of patients with atopic dermatitis but not psoriasis","volume":"88","author":"Mashiko","year":"2017","journal-title":"J\u00a0Dermatol Sci"},{"issue":"5","key":"10.1016\/j.det.2018.02.014_bib62","doi-asserted-by":"crossref","first-page":"a016337","DOI":"10.1101\/cshperspect.a016337","article-title":"Group 2 innate lymphoid cells in health and disease","volume":"7","author":"Kim","year":"2015","journal-title":"Cold Spring Harb Perspect Biol"},{"issue":"7","key":"10.1016\/j.det.2018.02.014_bib63","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1038\/ni805","article-title":"Human epithelial cells trigger dendritic cell mediated allergic inflammation by producing TSLP","volume":"3","author":"Soumelis","year":"2002","journal-title":"Nat Immunol"},{"issue":"5","key":"10.1016\/j.det.2018.02.014_bib64","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1038\/jid.2011.446","article-title":"IL-33 and ST2 in atopic dermatitis: expression profiles and modulation by triggering factors","volume":"132","author":"Savinko","year":"2012","journal-title":"J\u00a0Invest Dermatol"},{"issue":"8","key":"10.1016\/j.det.2018.02.014_bib65","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1084\/jem.20070406","article-title":"IL-25 augments type 2 immune responses by enhancing the expansion and functions of TSLP-DC\u2013activated Th2 memory cells","volume":"204","author":"Wang","year":"2007","journal-title":"J\u00a0Exp Med"},{"issue":"6, Supplement 1","key":"10.1016\/j.det.2018.02.014_bib66","doi-asserted-by":"crossref","first-page":"AB20","DOI":"10.1016\/j.jaad.2017.04.097","article-title":"A\u00a0phase 1 study of ANB020, an anti-IL-33 monoclonal antibody, in healthy volunteers","volume":"76","author":"Londei","year":"2017","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.det.2018.02.014_bib67","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1038\/nrrheum.2017.23","article-title":"The emerging safety profile of JAK inhibitors in rheumatic disease","volume":"13","author":"Winthrop","year":"2017","journal-title":"Nat Rev Rheumatol"},{"issue":"4","key":"10.1016\/j.det.2018.02.014_bib68","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1111\/jvp.12101","article-title":"Oclacitinib (APOQUEL) is a novel Janus kinase inhibitor with activity against cytokines involved in allergy","volume":"37","author":"Gonzales","year":"2014","journal-title":"J\u00a0Vet Pharmacol Ther"},{"issue":"1","key":"10.1016\/j.det.2018.02.014_bib69","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1111\/vde.12186","article-title":"A\u00a0blinded, randomized clinical trial comparing the efficacy and safety of oclacitinib and ciclosporin for the control of atopic dermatitis in client-owned dogs","volume":"26","author":"Little","year":"2015","journal-title":"Vet Dermatol"},{"issue":"3","key":"10.1016\/j.det.2018.02.014_bib70","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.jaad.2015.06.045","article-title":"Treatment of recalcitrant atopic dermatitis with the oral Janus kinase inhibitor tofacitinib citrate","volume":"73","author":"Levy","year":"2017","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"5","key":"10.1016\/j.det.2018.02.014_bib71","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1111\/bjd.14871","article-title":"Topical tofacitinib for atopic dermatitis: a phase IIa randomized trial","volume":"175","author":"Bissonnette","year":"2016","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.det.2018.02.014_bib72","unstructured":"Eli Lilly and Company Inc. Baricitinib meets primary endpoint in phase 2 study of patients with moderate-to-severe atopic dermatitis. 2017. Available at: http:\/\/www.prnewswire.com\/news-releases\/baricitinib-meets-primary-endpoint-in-phase-2-study-of-patients-with-moderate-to-severe-atopic-dermatitis-300518896.html. Accessed September 15, 2017."},{"key":"10.1016\/j.det.2018.02.014_bib73","unstructured":"AbbVie Inc. AbbVie's Upadacitinib (ABT-494) meets primary endpoint in phase 2b study in atopic dermatitis. 2017. Available at: https:\/\/news.abbvie.com\/news\/abbvies-upadacitinib-abt-494-meets-primary-endpoint-in-phase-2b-study-in-atopic-dermatitis.htm. Accessed September 11, 2017."},{"issue":"1","key":"10.1016\/j.det.2018.02.014_bib74","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1002\/ejp.767","article-title":"The pathogenesis of prurigo nodularis - \u201csuper-itch\u201d in exploration","volume":"20","author":"Zeidler","year":"2016","journal-title":"Eur J Pain"},{"issue":"5","key":"10.1016\/j.det.2018.02.014_bib75","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1111\/j.1468-3083.2012.04481.x","article-title":"Prurigo as a symptom of atopic and non-atopic diseases: aetiological survey in a consecutive cohort of 108 patients","volume":"27","author":"Iking","year":"2013","journal-title":"J\u00a0Eur Acad Dermatol Venereol"},{"issue":"5","key":"10.1016\/j.det.2018.02.014_bib76","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1111\/j.1600-0560.2009.01484.x","article-title":"Prurigo nodularis: systematic analysis of 58 histological criteria in 136 patients","volume":"37","author":"Weigelt","year":"2010","journal-title":"J\u00a0Cutan Pathol"},{"issue":"3","key":"10.1016\/j.det.2018.02.014_bib77","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.jdermsci.2010.03.020","article-title":"Low density of\u00a0sympathetic nerve fibers relative to substance P-positive nerve fibers in lesional skin of chronic pruritus and prurigo nodularis","volume":"58","author":"Haas","year":"2010","journal-title":"J\u00a0Dermatol Sci"},{"issue":"7","key":"10.1016\/j.det.2018.02.014_bib78","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1001\/archdermatol.2011.2918","article-title":"Treatment of refractory prurigo nodularis with lenalidomide","volume":"148","author":"Kanavy","year":"2012","journal-title":"Arch Dermatol"},{"issue":"2","key":"10.1016\/j.det.2018.02.014_bib79","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1159\/000331577","article-title":"Thalidomide in 42 patients with prurigo nodularis hyde","volume":"223","author":"Andersen","year":"2011","journal-title":"Dermatology"},{"issue":"7","key":"10.1016\/j.det.2018.02.014_bib80","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1001\/archderm.140.7.845","article-title":"Thalidomide treatment for prurigo nodularis in human immunodeficiency virus-infected subjects: efficacy and risk of neuropathy","volume":"140","author":"Maurer","year":"2004","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.det.2018.02.014_bib81","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1007\/s40266-015-0246-0","article-title":"Chronic pruritus in the elderly: pathophysiology, diagnosis and management","volume":"32","author":"Valdes-Rodriguez","year":"2015","journal-title":"Drugs Aging"},{"key":"10.1016\/j.det.2018.02.014_bib82","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.sder.2011.04.002","article-title":"Pruritus in elderly patients \u2013 eruptions of senescence","volume":"30","author":"Berger","year":"2011","journal-title":"Semin Cutan Med Surg"},{"issue":"5","key":"10.1016\/j.det.2018.02.014_bib83","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1016\/j.jaad.2015.11.029","article-title":"Immune dysregulation underlies a subset of patients with chronic idiopathic pruritus","volume":"74","author":"Xu","year":"2017","journal-title":"J\u00a0Am Acad Dermatol"}],"container-title":["Dermatologic Clinics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0733863518300251?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0733863518300251?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,10,16]],"date-time":"2019-10-16T00:22:24Z","timestamp":1571185344000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0733863518300251"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7]]},"references-count":83,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2018,7]]}},"alternative-id":["S0733863518300251"],"URL":"https:\/\/doi.org\/10.1016\/j.det.2018.02.014","relation":{},"ISSN":["0733-8635"],"issn-type":[{"value":"0733-8635","type":"print"}],"subject":[],"published":{"date-parts":[[2018,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immunomodulating Agents as Antipruritics","name":"articletitle","label":"Article Title"},{"value":"Dermatologic Clinics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.det.2018.02.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}